Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-703-0 | CAS number: 1474044-75-1
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Systemic availability is likely of one or several of the constituents or their metabolites. There are no experimental data to prove a bioaccumulating potential.
Key value for chemical safety assessment
Additional information
The substance is an UVCB product with a low water solubility (0.01 mg/L, calculated) and a log Pow of 7.62 (calculated).
The test item hydrolysis directly and quantitatively when it is solved in the buffer solutions. Thus the test item is not considered to be hydrolytically stable at pH 4, 7 and 9. The determination of the hydrolysis rate is not possible because of the very fast hydrolysis.
The following transformation product was detected: Methyl-1H-benzotriazole (tolyltriazole). Formaldehyd (CAS No. 50-00-0) and Diethanolamine (CAS No. 111-42-2) were proposed as further degradation products.
Simulation of microbial metabolism suggests tolylbenzotriazole (TTZ) as the predominant metabolite (OECD Toolbox, version 2.0). Therefore it can be expected that cleavage of the bulky molecules already takes place in the gastro-intestinal tract to some extent presenting TTZ and alkylamines for an enhanced uptake and distribution.
In an OECD 422 study performed with the read across candidate (see CSR for read across justification), systemic exposure could not be proven since compound-related findings were not evident other than stress-related effects seen in thymus and spleen. Clinical findings including mortality were observed suggesting uptake to some extent.
Metabolic behaviour is supposed to be similar for another structural analogue (see chapter 7.6.1 for details on molecule). It is postulated that this substance also yields to the main metabolite methylbenzotriazole after gastro-intestinal and/or liver cleavage. This substance provides the data of the genotoxicity testing for potential clastogenicity (chromosome aberration).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
